Literature DB >> 8971937

Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts.

J S Russell1, H Chi, L E Lantry, R E Stephens, P E Ward.   

Abstract

A recent study determined that cultured human skeletal muscle adult myoblasts, myotubes, and fibroblasts degraded angiotensins and kinins via neutral endopeptidase-24.11 (NEP-24.11: EC 3.4.24.11) and aminopeptidase N (APN: EC 3.4.11.2). Due to the possible importance of other peptides to skeletal muscle blood flow and function, the present study looked specifically at the metabolism of the neurokinins substance P (SP) and neurokinin A (NKA) by skeletal muscle peptidases. The results show that SP is degraded not only by NEP-24.11, but also sequentially by dipeptidyl(amino)peptidase IV (DAP IV: EC 3.4.14.5)/APN. NKA is unaffected by DAP IV but is metabolized by NEP-24.11 and APN. NEP-24.11 was inhibited by phosphoramidon (IC50 = 80 nM), thiorphan and ZINCOV, DAP IV by diprotin A (IC50 = 8 microM), and APN by amastatin (IC50 = 50 nM) and bestatin (IC50 = 100 microM). Skeletal muscle myocyte and fibroblast metabolism of SP and NKA may regulate local skeletal muscle vascular and extravascular functions including SP- and NKA-mediated nerve-induced vasodilation. Inhibition of both NEP-24.11 and DAP IV/APN may increase skeletal muscle blood flow and decrease peripheral vascular resistance via potentiation of local neurokinin levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971937     DOI: 10.1016/s0196-9781(96)00201-x

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

1.  Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.

Authors:  Alencia V Woodard-Grice; Amelia C Lucisano; James B Byrd; Elizabeth R Stone; William H Simmons; Nancy J Brown
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

2.  Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.

Authors:  James Brian Byrd; Karine Touzin; Saba Sile; James V Gainer; Chang Yu; John Nadeau; Albert Adam; Nancy J Brown
Journal:  Hypertension       Date:  2007-11-19       Impact factor: 10.190

Review 3.  Clinical Immunology Review Series: An approach to the patient with angio-oedema.

Authors:  S Grigoriadou; H J Longhurst
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

4.  Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.

Authors:  Nancy J Brown; Stuart Byiers; David Carr; Mario Maldonado; Barbara Ann Warner
Journal:  Hypertension       Date:  2009-07-06       Impact factor: 10.190

5.  Proteomic Changes during the Dermal Toxicity Induced by Nemopilema nomurai Jellyfish Venom in HaCaT Human Keratinocyte.

Authors:  Indu Choudhary; Duhyeon Hwang; Jinho Chae; Wonduk Yoon; Changkeun Kang; Euikyung Kim
Journal:  Toxins (Basel)       Date:  2021-04-27       Impact factor: 4.546

6.  Sitagliptin-associated angioedema.

Authors:  Aidar R Gosmanov; Eric C Fontenot
Journal:  Diabetes Care       Date:  2012-08       Impact factor: 19.112

7.  Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Authors:  Mark E Cooper; Vlado Perkovic; Per-Henrik Groop; Berthold Hocher; Uwe Hehnke; Thomas Meinicke; Audrey Koitka-Weber; Sandra van der Walt; Maximilian von Eynatten
Journal:  J Hypertens       Date:  2019-06       Impact factor: 4.844

Review 8.  Angioedema associated with dipeptidyl peptidase-IV inhibitors.

Authors:  Nicoletta Cassano; Eustachio Nettis; Elisabetta Di Leo; Francesca Ambrogio; Gino A Vena; Caterina Foti
Journal:  Clin Mol Allergy       Date:  2021-12-06

9.  Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS).

Authors:  Katsuhiro Ohyama; Junichiro Shindo; Tomohiro Takahashi; Hironori Takeuchi; Yusuke Hori
Journal:  Sci Rep       Date:  2022-07-30       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.